Hip ArthroplastyGeSTANCT03585647
Anesthetic Methods and Gene Expression Profile
An observational study of Hip Arthroplasty, run by University of Bologna at 1 site in Italy.
Trial summary
The study will analyze differentially regulated genes involved in oxidative stress and toxicology in peripheral blood mononuclear cells (PBMCs) of patients who underwent arthroplasty under three different anesthetic methods. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hip Arthroplasty
- What is being tested?
- hip arthroplasty
- Type of treatment
- Injection or infusion, Surgery or procedure
- How many people
- 99 participants
- Where
- 1 siteItaly
- Study dates
- 15 Sep 2014to 30 Nov 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients undergoing elective hip arthroplasty
Who may be able to join
- American Society of Anesthesiologists Classification (ASA Class) = I-II.
Who cannot join
- American Society of Anesthesiologists Classification (ASA Class) > III
- contraindication to spinal anaesthesia or lumbar catheter placement
- arterial hypertension not controlled by oral medication
- severe pulmonary
- cardiovascular disease
- renal disease
Show all 9Show fewer
- hepatic disease
- cerebrovascular disease
- psychiatric diseases
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Anesthetics Used for Regional vs General vs Integrated Anesthesia on the Modulation of 'Stress-responsive' Genes Involved in the Metabolism and Cellular Detoxification
The study will analyze differentially regulated genes involved in oxidative stress and toxicology in peripheral blood mononuclear cells (PBMCs) of patients who underwent arthroplasty under three different anesthetic methods. The investigator hypothesized that anesthesia procedures trigger toxicity, thus inducing changes in the messenger ribonucleic acid (mRNA) profile. The results may provide a more profound understanding of the molecular mechanism of anesthesia and in overcoming the adverse effects arising from their use.
Read the detailed description
By using a computer-generated randomization table, hospitalized patients undergoing elective hip arthroplasty will be randomly consecutively allocated to receive general (GA group), regional (RA group), or integrated (IA group) anesthesia. Patients with contraindication to spinal anesthesia or lumbar catheter placement, as well as obese patients, with arterial hypertension not controlled by oral medication, severe pulmonary, cardiovascular, renal, hepatic, cerebrovascular, or psychiatric diseases will be excluded from the study.
Whole blood samples (10 mL) will be obtained from all enrolled patients at three time points: early morning on the operation day (T0), after surgery (T1) and third day (T2) after surgery. The samples will be collected in heparin tubes and PBMCs will be isolated and used for gene expression analysis. Serum obtained after blood centrifugation will be used for hematological and biochemical analysis such as glutamate oxaloacetate transaminase (GOT), glutamate-pyruvate transaminase (GPT), bilirubin (BIL), creatinine (CREA), creatine phosphokinase (CPK), hemoglobin (HB).
The sample size was determined according to Lee- Whitmore * and G*Power Ftest for ANOVA Fixed effects, omnibus, one-way (Lee ML, Whitmore GA. Stat Med. 2002;21: 3543-3570). Assuming a Poisson distribution for the expected value of the false-positive gene expression of the 9 chosen genes and fixing at 1 the maximum expected value for false positives E(R0) and considering all the 84 genes as not differentially expressed (G0=G=9), the probability α for any single gene among the G genes that are not differentially expressed is given by α=E(R_0 )/G=1/9=0.011, with the Bonferroni correction it becomes α_c=(0.011)/3=0.037. This is the type I error of a false positive expression. Moreover, considering as primary endpoint the fold increase of the gene expression, assuming a log-normal distribution with standard deviation of 0.7 which is typical of moderate-high gene expression and therefore a conservative one for the sample size determination and imposing a minimum difference on logarithmic scale among the 3 groups of 0.5 with a power of at least 0.8 and a Bonferroni corrected type I error α=0.05/3=0.0167 (which is smaller and then conservative, than the previous α_c) the minimum sample size(G*POWER)^ for each group is 30 patients, by considering a 10% of drop-out , the chosen sample size was 33 patients per group which leads to a total sample size of 99 patients.
^F tests - ANOVA: Fixed effects, omnibus, one-way Analysis: A priori: Compute required sample size Input: Effect size f = 0.7 α err prob = 0.0167 Power (1-β err prob) = 0.8 Number of groups = 3 Output: Noncentrality parameter λ = 14.7000000 Critical F = 4.7803455 Numerator df = 2 Denominator df = 27 Total sample size = 30 Actual power = 0.8009945
The normal distribution of continuous variables will be evaluated by Kolmogorov-Smirnov test. The Chi-square test will be used to evaluate categorical variables. The differences between groups will be evaluated by means of parametric ANOVA tests followed by Tukey test. Multiple regression analysis will be performed to evaluate the influence of biochemical parameters on gene expression in response to anesthetics considering confounding factors such as age, gender, BMI, smoking. Values of p <0.05 will be considered statistically significant. All tests will be performed using software (SPSS, Chicago, USA).
- Conditions
- Hip Arthroplasty
- Being tested
- hip arthroplasty
- Keywords
- General anesthesia, Regional anesthesia, Integrated anesthesia, Hip arthroplasty, Toxicological gene expression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
hip arthroplastyProcedure or surgery
Also called Hip prosthesis
Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
| Study group | Role | What they receive |
|---|---|---|
| GA-group | Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal. Receives: Procedure: hip arthroplasty | |
| RA-group | Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set.
A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine. Receives: Procedure: hip arthroplasty | |
| IA-group | Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol. Receives: Procedure: hip arthroplasty |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes of Gene expression profile from baseline at time points
Effect of anesthesia techniques on the expression of genes indicative of stress and toxicity
Measured: Gene expression will be evaluated in PBMCs at baseline (T0), up-30 min after surgery (T1) and on the third day (T2) after surgery.
Secondary outcomes (1)
Relationship between deregulated genes and hepatic/renal cytotoxicity from baseline at time points
Multiple regression analysis of deregulated gene expression values (relative expression) and HB (mg/ml), hepatic markers such as GOT, GPT, BIL (mg/dl), and renal markers including CREA and CPK (mg/dl) will been performed. The results will be reported as coefficient of regression (r) with statistical significance p<0.05.
Measured: Biochemical analysis have been evaluated in blood collected at baseline (T0), up-30 min after surgery (T1) and on the third day (T2) after surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2018
- Study start15 Sep 2014
- Primary completion20 Jun 2015
- Study completion30 Nov 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Hip ArthroplastyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 99 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Bologna
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, RAlleva, University of Bologna
- Investigators
- Battista Borghi, MD, Study director, Rizzoli Orthopaedic Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03585647
- Sponsor's protocol ID
- 12630
- Acronym
- GeSTA
- Status last verified
- Apr 2019
- First submitted
- 14 Jun 2018
- Last updated
- 17 Apr 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is not a plan to make individual patient data (IPD) available
Publications
Alleva R, Tomasetti M, Solenghi MD, Stagni F, Gamberini F, Bassi A, Fornasari PM, Fanelli G, Borghi B. Lymphocyte DNA damage precedes DNA repair or cell death after orthopaedic surgery under general anaesthesia. Mutagenesis. 2003 Sep;18(5):423-8. doi: 10.1093/mutage/geg013.
PubMed 12960410Borghi B, Casati A, Iuorio S, Celleno D, Michael M, Serafini PL, Alleva R. Effect of different anesthesia techniques on red blood cell endogenous recovery in hip arthroplasty. J Clin Anesth. 2005 Mar;17(2):96-101. doi: 10.1016/j.jclinane.2004.05.005.
PubMed 15809124Nakazato K, Yoshida Y, Takemori K, Kobayashi K, Sakamoto A. Expressions of genes encoding drug-metabolizing enzymes are altered after sevoflurane, isoflurane, propofol or dexmedetomidine anesthesia. Biomed Res. 2009 Feb;30(1):17-24. doi: 10.2220/biomedres.30.17.
PubMed 19265259Ishikawa M, Tanaka S, Arai M, Genda Y, Sakamoto A. Differences in microRNA changes of healthy rat liver between sevoflurane and propofol anesthesia. Anesthesiology. 2012 Dec;117(6):1245-52. doi: 10.1097/ALN.0b013e3182746676.
PubMed 23090150Alleva R, Tognu A, Tomasetti M, Benassi MS, Pazzaglia L, van Oven H, Vigano E, De Simone N, Pacini I, Giannone S, Gagic S, Borghi R, Picone S, Borghi B. Effect of different anaesthetic techniques on gene expression profiles in patients who underwent hip arthroplasty. PLoS One. 2019 Jul 25;14(7):e0219113. doi: 10.1371/journal.pone.0219113. eCollection 2019.
PubMed 31344051
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Anesthetics Used for Regional vs General vs Integrated Anesthesia on the Modulation of 'Stress-responsive' Genes Involved in the Metabolism and Cellular Detoxification
- ClinicalTrials.gov ID
- NCT03585647
- Acronym / sponsor ID
- GeSTA / 12630
- Conditions
- Hip Arthroplasty
- Keywords
- General anesthesia, Regional anesthesia, Integrated anesthesia, Hip arthroplasty, Toxicological gene expression
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 99 participants (actual)
- Lead sponsor
- University of BolognaUniversity, hospital or other
- Study start
- 15 Sep 2014 (actual)
- Primary completion
- 20 Jun 2015 (actual)
- Study completion
- 30 Nov 2016 (actual)
- First posted
- 13 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will analyze differentially regulated genes involved in oxidative stress and toxicology in peripheral blood mononuclear cells (PBMCs) of patients who underwent arthroplasty under three different anesthetic methods. The investigator hypothesized that anesthesia procedures trigger toxicity, thus inducing changes in the messenger ribonucleic acid (mRNA) profile. The results may provide a more profound understanding of the molecular mechanism of anesthesia and in overcoming the adverse effects arising from their use.
Detailed description
By using a computer-generated randomization table, hospitalized patients undergoing elective hip arthroplasty will be randomly consecutively allocated to receive general (GA group), regional (RA group), or integrated (IA group) anesthesia. Patients with contraindication to spinal anesthesia or lumbar catheter placement, as well as obese patients, with arterial hypertension not controlled by oral medication, severe pulmonary, cardiovascular, renal, hepatic, cerebrovascular, or psychiatric diseases will be excluded from the study.
Whole blood samples (10 mL) will be obtained from all enrolled patients at three time points: early morning on the operation day (T0), after surgery (T1) and third day (T2) after surgery. The samples will be collected in heparin tubes and PBMCs will be isolated and used for gene expression analysis. Serum obtained after blood centrifugation will be used for hematological and biochemical analysis such as glutamate oxaloacetate transaminase (GOT), glutamate-pyruvate transaminase (GPT), bilirubin (BIL), creatinine (CREA), creatine phosphokinase (CPK), hemoglobin (HB).
The sample size was determined according to Lee- Whitmore * and G*Power Ftest for ANOVA Fixed effects, omnibus, one-way (Lee ML, Whitmore GA. Stat Med. 2002;21: 3543-3570). Assuming a Poisson distribution for the expected value of the false-positive gene expression of the 9 chosen genes and fixing at 1 the maximum expected value for false positives E(R0) and considering all the 84 genes as not differentially expressed (G0=G=9), the probability α for any single gene among the G genes that are not differentially expressed is given by α=E(R_0 )/G=1/9=0.011, with the Bonferroni correction it becomes α_c=(0.011)/3=0.037. This is the type I error of a false positive expression. Moreover, considering as primary endpoint the fold increase of the gene expression, assuming a log-normal distribution with standard deviation of 0.7 which is typical of moderate-high gene expression and therefore a conservative one for the sample size determination and imposing a minimum difference on logarithmic scale among the 3 groups of 0.5 with a power of at least 0.8 and a Bonferroni corrected type I error α=0.05/3=0.0167 (which is smaller and then conservative, than the previous α_c) the minimum sample size(G*POWER)^ for each group is 30 patients, by considering a 10% of drop-out , the chosen sample size was 33 patients per group which leads to a total sample size of 99 patients.
^F tests - ANOVA: Fixed effects, omnibus, one-way Analysis: A priori: Compute required sample size Input: Effect size f = 0.7 α err prob = 0.0167 Power (1-β err prob) = 0.8 Number of groups = 3 Output: Noncentrality parameter λ = 14.7000000 Critical F = 4.7803455 Numerator df = 2 Denominator df = 27 Total sample size = 30 Actual power = 0.8009945
The normal distribution of continuous variables will be evaluated by Kolmogorov-Smirnov test. The Chi-square test will be used to evaluate categorical variables. The differences between groups will be evaluated by means of parametric ANOVA tests followed by Tukey test. Multiple regression analysis will be performed to evaluate the influence of biochemical parameters on gene expression in response to anesthetics considering confounding factors such as age, gender, BMI, smoking. Values of p <0.05 will be considered statistically significant. All tests will be performed using software (SPSS, Chicago, USA).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| GA-group | – | Procedure: hip arthroplastyPatients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal. |
| RA-group | – | Procedure: hip arthroplastyPatients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set. A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine. |
| IA-group | – | Procedure: hip arthroplastyPatients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients undergoing elective hip arthroplasty
Key inclusion criteria (1 listed)
- American Society of Anesthesiologists Classification (ASA Class) = I-II.
Key exclusion criteria (9 listed)
- American Society of Anesthesiologists Classification (ASA Class) > III
- contraindication to spinal anaesthesia or lumbar catheter placement
- arterial hypertension not controlled by oral medication
- severe pulmonary
- cardiovascular disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| hip arthroplastyAlso: Hip prosthesisHip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis. | Procedure or surgery | GA-group, IA-group, RA-group |
Primary outcome
Changes of Gene expression profile from baseline at time points
Time frame: Gene expression will be evaluated in PBMCs at baseline (T0), up-30 min after surgery (T1) and on the third day (T2) after surgery.
Effect of anesthesia techniques on the expression of genes indicative of stress and toxicity
1 secondary outcome
Relationship between deregulated genes and hepatic/renal cytotoxicity from baseline at time points
Time frame: Biochemical analysis have been evaluated in blood collected at baseline (T0), up-30 min after surgery (T1) and on the third day (T2) after surgery.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2019.
- Results publication: PubMed 12960410Alleva R, Tomasetti M, Solenghi MD, Stagni F, Gamberini F, Bassi A, Fornasari PM, Fanelli G, Borghi B. Lymphocyte DNA damage precedes DNA repair or cell death after orthopaedic surgery under general anaesthesia. Mutagenesis. 2003 Sep;18(5):423-8. doi: 10.1093/mutage/geg013.
- Results publication: PubMed 15809124Borghi B, Casati A, Iuorio S, Celleno D, Michael M, Serafini PL, Alleva R. Effect of different anesthesia techniques on red blood cell endogenous recovery in hip arthroplasty. J Clin Anesth. 2005 Mar;17(2):96-101. doi: 10.1016/j.jclinane.2004.05.005.
- Results publication: PubMed 19265259Nakazato K, Yoshida Y, Takemori K, Kobayashi K, Sakamoto A. Expressions of genes encoding drug-metabolizing enzymes are altered after sevoflurane, isoflurane, propofol or dexmedetomidine anesthesia. Biomed Res. 2009 Feb;30(1):17-24. doi: 10.2220/biomedres.30.17.
- Results publication: PubMed 23090150Ishikawa M, Tanaka S, Arai M, Genda Y, Sakamoto A. Differences in microRNA changes of healthy rat liver between sevoflurane and propofol anesthesia. Anesthesiology. 2012 Dec;117(6):1245-52. doi: 10.1097/ALN.0b013e3182746676.
- Derived from this study: PubMed 31344051Alleva R, Tognu A, Tomasetti M, Benassi MS, Pazzaglia L, van Oven H, Vigano E, De Simone N, Pacini I, Giannone S, Gagic S, Borghi R, Picone S, Borghi B. Effect of different anaesthetic techniques on gene expression profiles in patients who underwent hip arthroplasty. PLoS One. 2019 Jul 25;14(7):e0219113. doi: 10.1371/journal.pone.0219113. eCollection 2019.
- Individual participant dataSharing planned: No. There is not a plan to make individual patient data (IPD) available
Related trials for Hip Arthroplasty
RecruitingObservational study
The restor3d Outcomes Registry
Joint Replacement, Arthropathy
Not yet recruiting
Posterior Pericapsular Deep-gluteal Block
Pain, Postoperative
Enrolling by invitationPhase 2
Efficacy of Intravenous Oxytocin to Speed Recovery After THA
Total Hip Arthroplasty
Active, not recruiting
Developing an Opioid Taper Intervention Before Total Joint Arthroplasty
Arthritis Knee, Arthritis Hip
Recruiting
FRONT Block for Quality of Recovery After Total Hip Arthroplasty
Osteoarthritis of the Hip, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Battista Borghi, MD study director
Rizzoli Orthopaedic Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Arthroplasty, run by University of Bologna at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes of Gene expression profile from baseline at time points (time frame: Gene expression will be evaluated in PBMCs at baseline (T0), up-30 min after surgery (T1) and on the third day (T2) after surgery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03585647, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2019.